Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.26% | 3.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.26% | 3.57% | |||
| Cost of Revenue | -0.49% | 2.76% | |||
| Gross Profit | 3.60% | 4.67% | |||
| SG&A Expenses | -0.35% | -4.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.17% | -0.91% | |||
| Operating Income | 17.85% | 35.42% | |||
| Income Before Tax | 52.99% | 42.40% | |||
| Income Tax Expenses | -441.22% | 202.21% | |||
| Earnings from Continuing Operations | 63.58% | 39.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.58% | 39.84% | |||
| EBIT | 17.85% | 35.42% | |||
| EBITDA | 214.80% | 119.85% | |||
| EPS Basic | 63.65% | 40.04% | |||
| Normalized Basic EPS | 21.44% | 33.18% | |||
| EPS Diluted | 63.65% | 40.04% | |||
| Normalized Diluted EPS | 21.44% | 33.18% | |||
| Average Basic Shares Outstanding | 0.18% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||